- Home
- VYGR vs CRDF Comparison
VYGR vs CRDF Comparison
Compare VYGR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- CRDF
- Stock Information
- Founded
- VYGR 2013
- CRDF 1999
- Country
- VYGR United States
- CRDF United States
- Employees
- VYGR N/A
- CRDF N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VYGR Health Care
- CRDF Health Care
- Exchange
- VYGR Nasdaq
- CRDF Nasdaq
- Market Cap
- VYGR 165.5M
- CRDF 169.6M
- IPO Year
- VYGR 2015
- CRDF N/A
- Fundamental
- Price
- VYGR $2.74
- CRDF $3.35
- Analyst Decision
- VYGR Strong Buy
- CRDF Strong Buy
- Analyst Count
- VYGR 8
- CRDF 4
- Target Price
- VYGR $14.33
- CRDF $12.25
- AVG Volume (30 Days)
- VYGR 377.3K
- CRDF 839.8K
- Earning Date
- VYGR 05-06-2025
- CRDF 05-08-2025
- Dividend Yield
- VYGR N/A
- CRDF N/A
- EPS Growth
- VYGR N/A
- CRDF N/A
- EPS
- VYGR N/A
- CRDF N/A
- Revenue
- VYGR $66,958,000.00
- CRDF $587,000.00
- Revenue This Year
- VYGR N/A
- CRDF N/A
- Revenue Next Year
- VYGR $45.34
- CRDF N/A
- P/E Ratio
- VYGR N/A
- CRDF N/A
- Revenue Growth
- VYGR N/A
- CRDF N/A
- 52 Week Low
- VYGR $2.65
- CRDF $2.01
- 52 Week High
- VYGR $9.55
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- VYGR 33.88
- CRDF 63.72
- Support Level
- VYGR $2.71
- CRDF $2.81
- Resistance Level
- VYGR $2.99
- CRDF $3.43
- Average True Range (ATR)
- VYGR 0.18
- CRDF 0.19
- MACD
- VYGR -0.05
- CRDF 0.08
- Stochastic Oscillator
- VYGR 10.86
- CRDF 85.54
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.